1. Bertram GK 主编. 基础与临床药理学 (Basic & Clinical Pharmacology). 北京: 人民卫生出版社, McGraw-Hill. 第1版, 2001年2月.
2. Hardman JG, Limbird LE 主编. 治疗学的药理学基础 (Goodman & Gliman’s the Pharmacological basis of Therapeutics. 10th editon). 北京: 人民卫生出版社, McGraw-Hill. 第1版, 2002年2月.
3. Frishman WH, Sonnenblick EH 主编. 心血管药物治疗学 (Cardiovascular Pharmacotherpeutics). 西安: 世界图书出版公司, McGram-Hill Book Co Singapore, 1998年8月第1次重印.
4. 药物治疗学 (Pharmacotherapy, 4th edition). 北京: 科学出版社, McGram-Hill. 英文影印第1版, 2000年9月.
5. Topol S 主编. 心血管病学 (Teabook of Cardiovascular Medicine, 2nd edition). 济南: 山东科学技术出版社. 第1版, 2003年5月.
6. Nestler EJ, Hyman SE, Malenka RC 主编. 分子神经药理学龄前 (Molecular Neuropharmacology). 北京: 人民卫生出版社, McGram-Hill. 英文影印第1版, 2001年11月.
7. Mycek MJ, Harvey RA, Champe PC 主编. 图解药理学散 (Lippincott’s lllustrated Reviews: Pharmacology, 2nd edition). 北京: 中国协和医科大学出版社, Lippincott Williams & Wilkins. 英文影印第1版, 2002年1月.
8. 杨藻宸主编. 医用药理学. 北京: 人民卫出版社. 第3版, 1994年6月.
9. 杨宝峰主编. 药理学. 北京: 人民卫出版社. 第6版, 2003年8月.
10. 苏定冯主编.心血管药理学. 北京: 科学出版社. 第1版, 2001年10月.
11. 杨藻宸主编. 药理学和药物治疗学. 北京: 人民卫出版社. 第1版, 2000年8月.
12. 周宏灏主编. 分子药理学. 哈尔滨: 黑龙江科学技术出版社. 第1版, 1999年5月.
13. 李家泰主编. 临床药理学.北京: 人民卫生出版社.第2版, 1997年.
14. 陈修主编. 心血管药理学. 北京: 人民卫生出版社. 第3版, 2002年.


第二章 药物代谢动力学
1. Shargel L and Yu A.B.C: Applied Biopharmaceutics and Pharmacokinetics, 3rd ed, East Norwalk, Appleton & Lange, 1993.
2. Wilkinson GR. Pharmacokinetics: The Dynamics of Drug Absortion, Distribution, and Elimination. In: Hardman JG and Limbaird LE. Ed.The Pharamcological Basis of Therapeutics.New York. McGraw-Hill.2001,3-30.

第三章 药物效应动力学
1. Kenakin TP, Bond RA, Bonner TI. Definition of pharmacological receptors. Pharmacol Rev. 1992;44:351-62.
2. Stephenson RP. A modification of receptor theory. Br J Pharmacol. 1956;379:393

第四章 影响药物效应的因素
1. Moyle G.Double "d" drug danger. AIDS Read. 2003;13:15-16, 23-24.
2. Rogers JF, Nafziger AN, Bertino JS Jr. Pharmacogenetics affects dosing, efficacy, and toxicity of cytochrome P450-metabolized drugs. Am J Med. 2002;15;113:746-750.
3. Weinshilboum R. Inheritance and drug response. N Eng J Med. 2003 Feb 6;348(6): 529-537.
4. Zhou HH, Koshakji RP, Silberstein DJ, Wilkinson GR, Wood AJ. Altered sensitivity to and clearance of propranolol in men of Chinese descent as compared with American whites. N Eng J Med. 1989;320:565-570.

第五章 传出神经系统药理学概述
1. Jordan D. The autonomic nervous system and behaviour. Acta Neurol (Napoli).1991;13: 539-548.
2. Yates BJ, Stocker SD. Integration of somatic and visceral inputs by the brainstem: functional considerations. Exp Brain Res. 1998;119:269-275.

第六章 胆碱受体激动药和胆碱受体阻断药
1. Pitschner HF, Schlepper M, Schulte B, Volz C, Palm D, Wellstein A. Eelective antagonists reveal different functions of M cholinoceptor subtypes in humans. Trends Pharmacol Sci. 1989;Suppl:92-196.
2. Takayanagi I, Koike K, Satoh M, Okayasu A. Drug receptor mechanisms in smooth muscle: beta-chloroethylamine-sensitive and -resistant receptor mechanisms. Jpn J Pharmacol. 1997;73:1-22.
3. Takayanagi I, Koike K, Satoh M. Transition of drug receptor mechanisms. J Smooth Muscle Res. 1992;28:35-54.

第七章 抗胆碱酯酶药和胆碱酯酶复活药
1. Jokanovic M, Maksimovic M. Abnormal cholinesterase activity: understanding and interpretation. Eur J Clin Chem Clin Biochem. 1997;35:11-16.
2. Sidell FR. Clinical effects of organophosphorus cholinesterase inhibitors. J Appl Toxicol. 1994;14:111-113.

第八章 肾上腺素受体激动药
1. Arch JR. beta(3)-Adrenoceptor agonists: potential, pitfalls and progress. Eur J Pharmacol. 2002 ;12;440:99-107.
2. Civantos Calzada B, Aleixandre de Artinano A. Alpha-adrenoceptor subtypes. Pharmacol Res. 2001;44:195-208.
3. Waldeck B. Beta-adrenoceptor agonists and asthma--100 years of development. Eur J Pharmacol. 2002 ;7;445:1-12.

第九章 肾上腺素受体阻断药
1. Haeusler G. Pharmacology of beta-blockers: classical aspects and recent developments. J Cardiovasc Pharmacol. 1990;16 Suppl 5:S1-S9.
2. Wallukat G. The beta-adrenergic receptors. Herz. 2002;27:683-690.

第十章 局部麻醉药
1. Grant SA. The Holy Grail: long-acting local anaesthetics and liposomes. Best Pract Res Clin Anaesthesiol. 2002;16:345-352.
2. Leri F, Bruneau J, Stewart J. Understanding polydrug use: review of heroin and cocaine co-use. Addiction. 2003;98:7-22.
3. Meechan JG. Supplementary routes to local anaesthesia. Int Endod J. 2002;35:885-896.

第十一章 全身麻醉药
1. Rogers JF, Nafziger AN, Bertino JS Jr. Pharmacogenetics affects dosing, efficacy, and toxicity of cytochrome P450-metabolized drugs. Am J Med. 2002;15:746-750.
2. Tassonyi E, Charpantier E, Muller D, Dumont L, Bertrand D. The role of nicotinic acetylcholine receptors in the mechanisms of anesthesia. Brain Res Bull. 2002;57:133-150.
3. Zuurmond WW, Meert TF, Noorduin H. Partial versus full agonists for opioid-mediated analgesia-focus on fentanyl and buprenorphine. Acta Anaesthesiol Belg. 2002;53:193-201.

第十二章 镇静催眠药
1. Casellas P, Galiegue S, Basile AS. Peripheral benzodiazepine receptors and mitochondrial function. Neurochem Int. 2002;40:475-486.
2. Mason PE, Kerns WP 2nd. Gamma hydroxybutyric acid (GHB) intoxication. Acad Emerg Med. 2002;9:730-739.
3. Stahl SM. Selective actions on sleep or anxiety by exploiting GABA-A/benzodiazepine receptor subtypes. J Clin Psychiatry. 2002;63:179-180.

第十三章 抗精神失常药
1. Crider AM, Scheideler MA. Recent advances in the development of dopamine D(3)receptor agonists and antagonists. Mini Rev Med Chem. 2001;1:89-99.
2. Frazer A, Benmansour S. Delayed pharmacological effects of antidepressants. Mol Psychiatry. 2002;7 Suppl 1:S23-S28.
3. Jones HM, Pilowsky LS. Dopamine and antipsychotic drug action revisited. Br J Psychiatry. 2002;181:271-275.
4. Sawa A, Snyder SH. Schizophrenia: diverse approaches to a complex disease. Science. 2002;296:692-695.
5. Slassi A. Recent advances in 5-HT1B/1D receptor antagonists and agonists and their potential therapeutic applications. Curr Top Med Chem. 2002;2:559-574.
6. Tarsy D, Baldessarini RJ, Tarazi FI. Effects of newer antipsychotics on extrapyramidal function. CNS Drugs. 2002;16:23-45.

第十四章 抗癫痫药
1. Loscher W. Basic pharmacology of valproate: a review after 35 years of clinical use for the treatment of epilepsy. CNS Drugs. 2002;16:669-694.
2. Pitkanen A. Drug-mediated neuroprotection and antiepileptogenesis: animal data. Neurology. 2002;12;59:S27-S33.

第十五章 治疗帕金森病及其他运动障碍的药物
1. Factor SA, Friedman JH. The emerging role of clozapine in the treatment of movement disorders. Mov Disord. 1997;12:483-496.
2. Jankovic J. Complications and limitations of drug therapy for Parkinson's disease. Neurology. 2000;55(12 Suppl 6):S2-S6.
3. Stern MB. Contemporary approaches to the pharmacotherapeutic management of Parkinson's disease: an overview. Neurology. 1997;49(1 Suppl 1):S2-S9.
4. Tintner and Jackovic. Treatment option for Parkinson’s disease. Current Opinion in Neurology. 2002;15:467-476.

第十六章 中枢神经系统兴奋药
1. Donovan JL, DeVane CL. A primer on caffeine pharmacology and its drug interactions in clinical psychopharmacology. Psychopharmacol Bull. 2001 Summer;35:30-48.
2. Frank GC. The power of the perk. Understanding the health effects of caffeine. Adv Nurse Pract. 2002;10:43-47.

第十七章 解热镇痛抗炎药
1. Aspirin. New uses for an old standby. Mayo Clin Health Lett. 2002;20:7.
2. Kawai S. Recent development of selective cyclooxygenase-2 inhibitors. Nippon Rinsho. 2002;60:2370-2377.
3. Pham T. Comparative efficacy of antalgesics and noN-steroidal anti-inflammatory drugs. Presse Med. 2002;7;31:4S3-S6.
4. Richard Polisson. Nonsteroidal anti-inflammatory drugs: practical and theoretical considerations in their selection. Am J Med. 1996;2;100: 31-36.

第十八章 镇痛药
1. Andersen G, Christrup L, Sjogren P. Relationships among morphine metabolism, pain and side effects during long-term treatment: an update. J Pain Symptom Manage. 2003; 25: 74-91.
2. Przewlocki R, Przewlocka B. Opiods in chronic pain. Eur J Pharmacol. 2001; 429:79-91.
3. Rogers JF, Nafziger AN, Bertino JS Jr. Pharmacogenetics affects dosing, efficacy, and toxicity of cytochrome P450-metabolized drugs. Am J Med. 2002;15;113:746-750.

第十九章 钙通道阻滞药
1. Arekh AB & Penner R. Store Depletion and Calcium Influx. Pharmacology Review. 1997; 77:901.
2. Gibson A, McFadzean I, Wallace P, et al. Capacitative Ca2+ entry and the regulation of smooth muscle tone. TIPS. 1998;19:266.
3. Jackson WF. Ion Channels and Vascular Tone. Hypertension. 2000;35:173.
4. Zhu X & Birnbaumer L. Calcium Channels Formed by Mammalian Trp Homologues. NIPS. 1998;13:211.

第二十章 抗心肌缺血药
1. Deedwania PC, Carbajal EV. Role of beta blockade in the treatment of myocardial ischemia. Am J Cardiol. 1997; 80 suppl 2:S23-S28.
2. Kubler W. Secondary and primary prevention of coronary heart disease: platelet aggregation inhibitors and anticoagulants. Z Kardiol. 2002;91 Suppl 2:40-48.
3. Strashnyi VV, Lysenko AF. Evolution of the market of calcium dihydropyridinic antagonists and their use in the treatment of chronic forms of ischemic heart disease. Lik Sprava. 2002; 16-20.
4. Walenga JM, Fareed J. Current status on new anticoagulant and antithrombotic drugs and devices. Curr Opin Pulm Med. 1997;3:291-302.

第二十一章 抗高血压药
1. Fisher ND, Hollenberg NK. Is there a future for renin inhibitors? Expert Opin Investig Drugs. 2001;10:417-426.
2. Guidelines Subcommittee: 1999 World Health OrganizatioN-International Society of hypertinsion guidelines for the management of hypertension. J Hypertens. 1999; 17: 151-183.
3. Hollenberg NK, Sever PS. The past, present and future of hypertension management: a potential role for AT⑴-receptor antagonists. J Renin Angiotensin Aldosterone Syst. 2000;1:5-10.
4. Oluwole BO, Du W, Mills I, Sumpio BE. Gene regulation by mechanical forces. Endothelium. 1997;5:85-93.

第二十二章 治疗慢性心功能不全的药物
1. Haas S. Future potential indications for an oral thrombin inhibitor. Hamostaseologie. 2002;22:36-43.
2. Hermann DD. Beta-adrenergic blockade 2002: a pharmacologic odyssey in chronic heart failure. Congest Heart Fail. 2002;8:262-9;283.
3. Kohno M, Matsuzaki M. Drugs for the heart failure. Nippon Rinsho. 1994;52 Suppl(Pt 1):1072-1079.

第二十三章 抗心律失常药
1. Brembilla-Perrot B. Antiarrhythmic drugs in atrial fibrillation. Rev Prat. 2002; 15; 52: 1317-1323.
2. The search for novel antiarrhythmic strategies. Sicilian Gambit. Jpn Circ J. 1998; 62: 633-648.

第二十四章 调血脂药和抗动脉粥样硬化药
1. Boumendil EF. Descriptive study of lipid-modulating drug use in a French professional population. J Clin Epidemiol. 1994;47:1163-1171.
2. Lau BH. Suppression of LDL oxidation by garlic. J Nutr. 2001;131:985S-988S.
3. Malkonen M, Muona M, Manninen V. Studies on hypoxic dyslipidaemia. Effect of lipid modulating drugs. Acta Med Scand Suppl. 1982;668:130-135.
4. Miyazaki A, Horiuchi S. Development of new antiatherosclerotic agents--ACAT inhibitors and CETP inhibitors Nippon Rinsho. 1999;57:2842-2847.

第二十五章 利尿药和脱水药
1. Ambrosioni E, Bacchelli S. Delayed delivery diuretics: from pharmacology to clinical use. ardiologia. 1999;44 Suppl 1:533-536.
2. Paul S. Balancing diuretic therapy in heart failure: loop diuretics, thiazides, and aldosterone antagonists. Congest Heart Fail. 2002;8:307-312.
3. Ruzicka M, Leenen FH. Combination therapy as first-line treatment of arterial hypertension. Can J Cardiol. 2002;18:1317-27.

第二十六章 消化系统药
1. Plosker GL, Lamb HM. Diclofenac/Misoprostol. Pharmacoeconomic Implications of Therapy. Pharmacoeconomics. 1999;16:85-98.
2. Welage LS, Berardi RR. Evaluation of Omeprazole, Lansoprazole, Pantoprazole, and Rabeprazole in the Treatment of Acid-related Disease. J Am Pharm Assoc. 2000;40:52-62.

第二十七章 呼吸系统药
1. Campbell LM. From Adrenaline to Formoterol: Advances in Beta-agonist Therapy in the Treatment of Asthma. Int J Clin Pract. 2002;56:783-790.
2. Karlsson JA, Fuller RW. Pharmacological Regulation of the Cough Reflex—from Experimental Models to Antitussive Effects in Man. Pulm Pharmacol Ther. 1999; 12: 215-228.

第二十八章 子宫平滑肌药
1. de Groot AN, van Dongon PW, Vree TB, Hehster YA, van Roosmalen J. Ergot alkaloids. Current status and review of clinical pharmacology and theraputic use compared with other oxytocics in obstetrics and gynaecology. Drugs. 1998;56:523-535.
2. den Hertog CE, de Groot AN, van Dongen PW. History and Use of Oxytocics. Eur J Obstet Gynecol Reprod Biol. 2001;94:8-12.

第二十九章 肾上腺皮质激素类药物
1. Belvisi MG, Brown TJ, Wicks S, Foster ML. New Glucocorticosteroids with an improved therapeutic ratio? Pulm Pharmacol Ther. 2001;14:221-227.
2. Struthers AD. Aldosterone: cardiovascular assault. Am Heart J. 2002;144:S2-S7.
3. Szefler SJ. Pharmacodynamics and pharmacokinetics of budesonide: a new nebulized corticosteroid. J Allergy Clin Immunol. 1999;104:175-183.

第三十章 甲状腺激素和抗甲状腺药
1. Cavalieri RR. Iodine metabolism and thyroid physiology: current concepts.Thyroid.1997; 7: 177-181.
2. Cooper DS. Antithyroid drugs for the treatment of hyperthyroidism caused by Graves disease. Endocrinol Metab Clin North Am 1998;27:225-224.
3. Eng PH, Cardona GR, Fang SL, et al. Escape from the acute Wolff-Chaikoff effect is assocoiated with a decrease in thyroid sodium/iodide sympoter messenger ribonucleic acid and protein. Endocrinology 1999;140:3404-3410.
4. Eskandari S, Loo DD, Dai G, et al. Thyroid Na+/I- sympoter, mechanism, stoichiometry, and specificity. J Biol Chem 1997;272:27230-27238.

第三十一章 胰岛素及口服降血糖药
1. Gin H, Rigalleau V. Oral anti diabetic polychemotherapy in type 2 diabetes mellitus. Diabetes Metab. 2002;28:350-353.
2. Horton ES, Clinkingbeard C, Gatlin M, et al. Nateglinide alone and in combination with metformin improves glycemia control by reducing mealtime glucose levels in type 2 diabetes. Diabetes Care. 2000;23:1660-1665.
3. UK Prospective Diabetes Study Group. Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complication in patients with type 2 diabetes (UKPDS 3). Lancet. 1998a;352:837-853.

第三十二章 性激素类与避孕药物
1. Genazzani AR, Bernardi F. Estrogen effects on neuroendocrine function: the new challenge of pulsed therapy. Climacteric. 2002;5 Suppl 2:50-56.
2. Pitkin J. Compliance with estrogen replacement therapy: current issues. Climacteric. 2002; 5 Suppl 2:12-19.

第三十三章 组胺与抗组胺药
1. Simons FE, Simons KJ. Clinical pharmacology of H1-antihistamines. Clin Allergy Immunol. 2002;17:141-178.
2. Winbery SL, Lieberman PL. Histamine and antihistamine in anaphylaxis. Clin Allergy Immunol. 2002;17:287-317.

第三十四章 5-羟色胺和5-羟色胺受体阻断药
1. Hoyer D, Hannon JP, Martin GR. Molecular, pharmacological and functional diversity of 5-HT receptors. Pharmacol Biochem Behav. 2002;71:533-554.
2. Jones BJ, Blackburn TP. The medical benefit of 5-HT research. Pharmacol Biochem Behav. 2002;71:555-568.

第三十五章 抗贫血药
1. Burns DL, Mascioli EA, Bistrian BR. Parenteral iron dextran therapy: a review. Nutrition. 1995;11:163-168.
2. Kapur D, Agarwal KN, Agarwal DK. Nutritional anemia and its control. Indian J Pediatr. 2002;69:607-616.
3. Macdougall IC. Strategies for iron supplementation: oral versus intravenous. Kidney Int Suppl. 1999;69:S61-S66.

第三十六章 作用于凝血系统的药物
1. Burns DL, Mascioli EA, Bistrian BR. Parenteral iron dextran therapy: a review. Nutrition. 1995;11:163-168.
2. Kapur D, Agarwal KN, Agarwal DK. Nutritional anemia and its control. Indian J Pediatr. 2002;69:607-616.
3. Macdougall IC. Strategies for iron supplementation: oral versus intravenous. Kidney Int Suppl. 1999;69:S61-S66.

第三十七章 免疫抑制药
1. Jacobsohn DA. Novel theraputics for the treatment of graft-versus-host disease. Expert Opin Investig Drugs. 2002; 9:1271-1280.
2. Jacobsohn DA, Vogelsang GB. Novel Pharmacotheraputic approaches to prevention and treatment of GVHD. Drugs. 2002; 62: 879-889.

第三十八章 免疫兴奋药
1. Mocellin S, Rossi CR, Lise M, Marincola FM. Adjuvant immunotherapy for solide tumors: from promise to clinical application. Cancer Immunol Immunother. 2002;51:583-595.
2. Rhodes J. Discovery of immunopotentiatory drugs: current and future strategies. Clin Exp Immunol. 2002;130:363-369.

第三十九章 抗菌药物概论
1. Bassetti M, Melica G, Cenderello G, Rosso R, Di Biagio A, Bassetti D. Gram-positive bacterial resistance. A challenge for the next millennium. Panminerva Med. 2002; 44: 179-184.
2. Coates A, Hu Y, Bax R, Page C. The future challenges facing the development of new antimicrobial drugs. Nat Rev Drug Discov. 2002;1:895-910.
3. Labro MT. Antibiotics as anti-inflammatory agents. Curr Opin Investig Drugs. 2002; 3: 61-68.
4. Stewart PS, Costerton JW. Antibiotic resistance of bacteria in biofilms. Lancet. 2001;358: 135-138.

第四十章 ?-内酰胺类抗生素
1. Mascaretti OA, Danelon GO, Laborde M, Mata EG, Setti EL. Recent advances in the chemistry of beta-lactam compounds as selected active-site serine beta-lactamase inhibitors. Curr Pharm Des. 1999;5:939-953.
2. Massova I, Mobashery S. Structural and mechanistic aspects of evolution of beta-lactamases and penicillin-binding proteins. Curr Pharm Des. 1999;5:929-937.
3. Page MI. The reactivity of beta-lactams, the mechanism of catalysis and the inhibition of beta-lactamases. Curr Pharm Des. 1999;5:895-913.

第四十一章 氨基苷类抗生素
1. Ambrose PG, Owens RC Jr, Garvey MJ, Jones RN. Pharmacodynamic considerations in the treatment of moderate to severe pseudomonal infections with cefepime. J Antimicrob Chemother. 2002;49:445-453.
2. Bolzan AD, Bianchi MS. Genotoxicity of streptozotocin. Mutat Res. 2002;512:121-134.
3. Geller DE, Pitlick WH, Nardella PA, Tracewell WG, Ramsey BW. Pharmacokinetics and bioavailability of aerosolized tobramycin in cystic fibrosis. Chest. 2002;122:219-226.

第四十二章 大环内酯类、林可霉素类及多肽类抗生素
1. Paganini H, Marin M. Pharmacokinetic characteristics and antimicrobial spectrum of teicoplanin. Medicina (B Aires). 2002; 62 Suppl 2:52-55.
2. Smilack JD, Wilson WR, Cockerill FR 3rd. Tetracyclines, chloramphenicol, erythromycin, clindamycin, and metronidazole. Mayo Clin Proc. 1991;66:1270-1280.
3. Trefzer A, Salas JA, Bechthold A. Genes and enzymes involved in deoxysugarbiosynthesis in bacteria. Nat Prod Rep. 1999; 16: 283-299.

第四十三章 四环素类及氯霉素类抗生素
1. Leviton I. Inhibitors of protein synthesis. Cancer Invest. 1999;17:87-92.
2. Watanabe N, Kasahara A, Nakada K, Hayashi J. Mutagens inducing mutations in mammalian mitochondrial DNA. Nippon Rinsho. 2002;60:35-38.

第四十四章 人工合成抗菌药
1. Hooper DC. Mechanism of action and resistance of older and newer fluroquinolones. Clin Infec Dis. 2000;31:S24-S28.
2. Labeling requirements for systemic antibacterial drug products intended for human use. Final rule. Fed Regist. 2003; 68:6062-6081.
3. Norrby SR. Side-effects of quinolones: comparisons between quinolones and other antibiotics. Eur J Clin Microbiol Infect Dis. 1991;10:378-383.

第四十五章 抗结核病药及抗麻风病药
1. Abe C. Multidrug-resistant tuberculosis. Drug susceptibility testing and its standardization. Kekkaku. 1998;73:649-655.
2. Talwar GP. An immunotherapeutic vaccine for multibacillary leprosy. Int Rev Immunol. 1999;18:229-249.
3. Volmink J, Garner P. Interventions for promoting adherence to tuberculosis management. Cochrane Database Syst Rev. 2000;2:CD000010.
4. Wada M. The adverse reactions of anti-tuberculosis drugs and its management. Nippon Rinsho. 1998;56:3091-3095.

第四十六章 抗真菌药和抗病毒药
1. de Clercq E. Highlights in the development of new antiviral agents. Mini Rev Med Chem. 2002;2:163-175.
2. Fishman JA. Summary: future directions in antifungal therapy. Transpl Infect Dis. 2002; 4 Suppl 3:67-68.
3. Rebora A. Antiviral drugs: unapproved uses, dosages, or indications. Clin Dermatol. 2002; 20:474-480.

第四十七章 抗寄生虫药
1. Dominguez JN. Chemotherapeutic Agents Agonist Malaria: What Next After Chloroquine? Curr Top Med Chem. 2002;2:1173-1185.
2. Ridley RG. Medical Need, Scientific Opportunity and the Drive for Antimalarial Drugs. Nature. 2002;7;415:686-693.
3. Webbe G. Community-wide Treatment of Schistosomiasis with Praziquantel. Trop Doct. 1999;29:172-176.

第四十八章 抗恶性肿瘤药物
1. Mormont MC, Levi F. Cancer chronotherapy: priciples, applications, and perspectives. Cancer. 2003; 97: 155-169.
2. Schwartsmann G, Ratain MJ, Cragg GM, Wong JE, Saijo N, Parkinson DR, Fujiwara Y, Pazdur R, Nemman DJ, Dagher R, DiLeone L. Anticancer drug discovery and development throughout the world. J Clin Oncol. 2002; 20: 47-59.